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Abstract
 
Background.
 
Platelet glycoprotein IIb/IIIa is
a membrane receptor for ﬁbrinogen and von Willebrand
factor, and it has an important role in platelet aggrega-
tion. It is known to be involved in the pathogenesis of
acute coronary syndromes. Previously, we found a high
frequency of a particular polymorphism, 
 
Pl
 
A2
 
,
 
 of the gene
encoding glycoprotein IIIa in kindreds with a high preva-
lence of premature myocardial infarction.
 
Methods.
 
To investigate the relation between the 
 
Pl
 
A2
 
polymorphism and acute coronary syndromes, we con-
ducted a case–control study of 71 case patients with my-
ocardial infarction or unstable angina and 68 inpatient
controls without known heart disease. The groups were
matched for age, race, and sex. We used two methods
to determine the 
 
Pl
 
A 
 
genotype: reverse dot blot hybridiza-
tion and allele-speciﬁc restriction digestion.
 
Results.
 
The prevalence of 
 
Pl
 
A2
 
 was 2.1 times higher
among the case patients than among the controls (39.4
percent vs. 19.1 percent, P
 

 
0.01). In a subgroup of pa-
tients whose disease began before the age of 60 years,
the prevalence of 
 
Pl
 
A2
 
 
 
was 50 percent, a value that was
3.6 times that among control subjects under 60 years of
age (13.9 percent, P
 

 
0.002). Among subjects with the
 
Pl
 
A2
 
 polymorphism, the odds ratio for having a coronary
event was 2.8 (95 percent conﬁdence interval, 1.2 to 6.4).
In the patients less than 60 years of age at the onset of
disease, the odds ratio was 6.2 (95 percent conﬁdence
interval, 1.8 to 22.4).
 
Conclusions.
 
We observed a strong association be-
tween the 
 
Pl
 
A2
 
 
 
polymorphism of the glycoprotein IIIa gene
and acute coronary thrombosis, and this association was
strongest in patients who had had coronary events before
the age of 60 years. (N Engl J Med 1996;334:1090-4.)
 

 
1996, Massachusetts Medical Society.
 
From the Department of Medicine, Divisions of Cardiology (E.J.W., S.P.S.,
L.C.B., J.L.W., G.G., P.J.G.-C.) and Hematology (E.J.W., P.F.B., T.S.K.), the De-
partment of Pathology (P.F.B., T.S.K.), and the Department of Cell Biology and
Anatomy (P.J.G.-C.), Johns Hopkins University School of Medicine; and Johns
Hopkins University School of Hygiene and Public Health (M.T.) — both in Bal-
timore. Address reprint requests to Dr. Goldschmidt-Clermont at Bernard Lab-
oratory, Ross 1023, Johns Hopkins Medical School, 720 Rutland Ave., Baltimore,
MD 21205.
Supported by grants from the National Institutes of Health (HL49762 and
NR02241), a grant from the Rebecca and Bernard Bernard Foundation, the Cic-
carone Center for the Prevention of Heart Disease, and the Rogers–Wilbur Foun-
dation. Dr. Goldschmidt-Clermont is an Established Investigator of the American
Heart Association.
S
 
TUDIES indicate that myocardial infarction and un-
stable angina result from the formation of a platelet
aggregate at the site of a ruptured coronary atheroscle-
rotic plaque.
 
1-7
 
 The formation of such aggregates re-
quires the binding of ﬁbrinogen and von Willebrand fac-
tor to the receptor, glycoprotein IIb/IIIa, on the platelet
surface.
 
6,8,9
 
 Large trials have demonstrated a marked
beneﬁt of various inhibitors of platelet function in both
preventing and reducing the mortality and morbidity as-
sociated with unstable coronary syndromes.
 
10-26
 
 Addi-
tional studies have linked ex vivo platelet reactivity to
outcome in patients after myocardial infarction.
 
27
 
 In
sum, there is strong evidence that platelets, and glyco-
protein IIb/IIIa in particular, have an important role in
the pathogenesis of acute coronary syndromes.
Platelet-membrane glycoproteins are highly poly-
morphic and can be recognized as alloantigens or au-
toantigens.
 
28
 
 The alloimmune thrombocytopenias are
due to the incompatibility of epitopes on the various
platelet-surface glycoproteins.
 
29
 
 The alloantigen re-
ferred to as Pl
 
A
 
 or Zw is the one most frequently im-
plicated in syndromes of immune-mediated platelet
destruction.
 
30,31
 
 Kunicki and Aster demonstrated that
anti-Pl
 
A1
 
 antiserum from Pl
 
A1
 
-negative persons reacted
with platelet glycoprotein IIIa.
 
32
 
 Subsequently, New-
man et al. identiﬁed the molecular basis of this poly-
morphism: persons positive for Pl
 
A1
 
 have a leucine at
position 33 of mature glycoprotein IIIa; persons posi-
tive for Pl
 
A2
 
 have a proline at this position, which is the
result of the substitution of cytosine for thymidine at
position 1565 in exon 2 of the glycoprotein IIIa gene.
 
33
 
We recently determined the allelic frequencies of 
 
Pl
 
A1
 
and 
 
Pl
 
A2
 
 in several racial and ethnic groups in the met-
ropolitan Baltimore area.
 
34
 
Previously, we found an unexpectedly high frequency
of family members homozygous for 
 
Pl
 
A2
 
 in kindreds
with a high prevalence of acute coronary events at a
relatively young age (under 60 years).
 
35
 
 This observa-
tion led us to postulate that the presence of at least one
 
Pl
 
A2
 
 allele may be related to the development of symp-
tomatic unstable coronary heart disease. We conducted
a case–control study to examine whether there was an
association between the 
 
Pl
 
A2
 
 allele and unstable coro-
nary syndromes, especially in persons less than 60 years
of age.
 
M
 
ETHODS
 
Selection of Case Patients and Control Subjects
 
Studies on case patients and control subjects were approved by the
Joint Committee for Clinical Investigation of Johns Hopkins Univer-
sity and Hospital. Genotypic analyses were performed on 71 consec-
utive case patients admitted to the Coronary Care Unit of Johns Hop-
kins Hospital with an established diagnosis of myocardial infarction
or unstable angina as deﬁned by World Health Organization crite-
ria. Similar genotypic analyses were performed on control subjects
matched with the case patients for age, race, and sex, but who had no
documented history of either stable or unstable angina or myocardial
infarction. The control subjects were selected by reviewing patient
charts from a population of patients admitted to the general medical
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and intensive care services of the hospital. We selected 68 consecutive
subjects who fulﬁlled these criteria.
 
Demographic Characteristics
 
Demographic data were obtained on each subject from the ofﬁcial
medical record at the time of enrollment and included the current age
(for control subjects), the age at the time of a ﬁrst event (for case pa-
tients), sex, smoking history, blood pressure, total serum cholesterol
level, diabetes status, and history of coronary events. Because the
prevalence of the 
 
Pl
 
A2
 
 allele is known to be lower among blacks than
among whites, we limited the study to the white population.
 
34,36
 
Determination of 
 
Pl
 
A
 
 Genotypes
 
Genomic DNA was isolated from 200 
 
m
 
l of whole blood as previ-
ously described or with the QIAamp blood kit (Qiagen, Chatsworth,
Calif.).
 
37
 
 To detect the substitution of cytosine for thymidine respon-
sible for the 
 
Pl
 
A2
 
 polymorphism at position 1565 in exon 2 of the gly-
coprotein IIIa gene, we used both reverse dot blot hybridization and
allele-speciﬁc restriction digestion (exon numbering and nucleotide
sequence are from Zimrin et al.
 
38
 
). Exon 2 was ampliﬁed from genom-
ic DNA from case patients or controls in a polymerase chain reaction
(PCR) with primers ﬂanking the exon, as previously described.
 
39
 
 For
the reverse dot blot hybridization reaction, oligonucleotides speciﬁc
for either the 
 
Pl
 
A1
 
 or 
 
Pl
 
A2
 
 allele were covalently attached to ﬁlters and
hybridized with biotinylated PCR products of glycoprotein IIIa exon
2, and reactivity was assessed by an enhanced chemiluminescence
technique, as described previously.
 
34,37
 
 These allele-speciﬁc hybridiza-
tion data were conﬁrmed with restriction-enzyme digestion with 
 
Msp
 
I
and 
 
Nci
 
I (New England Biolabs, Beverly, Mass.), which are able to
distinguish the 
 
Pl
 
A1 
 
allele from the 
 
Pl
 
A2
 
 allele because new restriction
sites are generated as the result of the 
 
Pl
 
A2
 
 polymorphism. Exon 2
PCR products were digested separately with both enzymes, and the
resulting fragments were analyzed on a 3 percent agarose gel. The re-
sults of both techniques were conﬁrmed by at least two independent
investigators who were unaware of the origin of the DNA.
 
Statistical Analysis
 
The size of the sample was established after pilot studies indicated
that the prevalence of 
 
Pl
 
A2
 
 among the case patients would be approx-
imately 40 percent and the expected prevalence in control subjects
would not exceed 20 percent. With the expectation that a difference of
this magnitude would strongly support the concept that 
 
Pl
 
A2
 
 is a sig-
niﬁcant genetic risk factor, and with a one-sided alpha error of 0.05,
the size of the sample was set at 71 to limit the beta error to 0.1. Stu-
dent’s t-test was used to compare established risk factors for coronary
heart disease in the case patients and the control subjects, with a two-
tailed test used for the continuous variables. A P value of 0.05 or less
was considered to indicate statistical signiﬁcance. Discrete data (in-
cluding data on the 
 
Pl
 
A
 
 alleles) were analyzed by the chi-square test.
The strength of the association of the 
 
Pl
 
A2
 
 genetic factor with the oc-
currence of acute coronary events was estimated by calculation of the
odds ratios with EpiInfo software (version 6, Centers for Disease Con-
trol and Prevention, Atlanta) and the Cornﬁeld method for the calcu-
lation of 95 percent conﬁdence intervals. The relative strength of asso-
ciation of other risk factors was measured in a similar manner. The
signiﬁcance of the difference in the odds ratios was not tested, since
the sample size was not designed for such analyses. The relation of the
 
Pl
 
A
 
 allele to each of the remaining predictor variables was examined
by bivariate chi-square analysis. Finally, the association of the 
 
Pl
 
A2
 
 al-
lele with coronary events, standardized for the other risk factors, was
determined by the multiple logistic-regression method with the Stata
statistical package (version 4.0, Stata, College Station, Tex.).
 
R
 
ESULTS
 
Characteristics of the Study Population
 
Table 1 shows the prevalence of selected risk factors
for coronary heart disease among the case patients and
controls. The two groups were matched according to
age, race, and sex, and there were therefore no signiﬁ-
cant differences in these variables. Owing to the sample
size, the only risk factor that differed signiﬁcantly be-
tween the groups was smoking status (P
 

 
0.05).
 
Prevalence of
 
 
 
Pl
 
A2
 
 
 
Genotyping results for 3 of the 71 case patients are
shown in Figure 1, demonstrating the three possible 
 
Pl
 
A
 
allelic combinations. Table 2 summarizes the genotyp-
ing data for all case patients and controls. The preva-
lence of 
 
Pl
 
A2
 
 
 
among the case subjects was 39.4 percent
(percentage of subjects who were either heterozygous
[
 
Pl
 
A1
 
/
 
Pl
 
A2
 
] or homozygous [
 
Pl
 
A2
 
/
 
Pl
 
A2
 
]), a value that was
signiﬁcantly higher than the prevalence among the 68
controls (19.1 percent, P
 

 
0.01). The association be-
tween 
 
Pl
 
A2
 
 
 
and coronary events was even stronger in
patients who were less than 60 years of age when they
had their ﬁrst coronary event. Of the 42 such patients,
50 percent carried at least one 
 
Pl
 
A2
 
 allele, as compared
with 13.9 percent of the 36 controls who were less than
60 years of age (P
 

 
0.002).
 
Comparison of Major Risk Factors for Coronary Heart 
Disease
 
Among the major risk factors for coronary heart dis-
ease examined in this study, the risk factor associated
with the highest estimated odds ratio was carriage of
the 
 
Pl
 
A2
 
 
 
allele
 
 
 
(odds ratio, 2.8; 95 percent conﬁdence in-
terval, 1.2 to 6.4), followed in order by smoking (odds
ratio, 2.2; 95 percent conﬁdence interval, 1.0 to 4.8),
hypertension (systolic blood pressure, 
 

 
140 mm Hg)
(odds ratio, 1.9; 95 percent conﬁdence interval, 0.9 to
3.9), and hypercholesterolemia (total serum cholesterol
level, 
 

 
200 mg per deciliter [5.2 mmol per liter]) (odds
ratio, 1.3; 95 percent conﬁdence interval, 0.5 to 3.0)
(Table 3). The prevalence of diabetes mellitus was sim-
 
*Student’s t-test (for continuous variables) and the chi-square test (for
discrete variables) were used to compare the values for case patients and
controls.
†Plus–minus values are means 
 

 
SD; for the case patients, the value re-
fers to the age at onset of myocardial infarction or unstable angina, not the
current age.
‡Hypertension was deﬁned as a systolic blood pressure 
 

 
140 mm Hg
at the time of admission to the hospital.
§Hypercholesterolemia was deﬁned as a total serum cholesterol level
 

 
200 mg per deciliter (5.2 mmol per liter) at the time of admission to the
hospital.
 
Table 1. Prevalence of Selected Risk Factors for
Coronary Heart Disease among Case Patients
and Controls.
 
R
 
ISK
 
 F
 
ACTOR
 
C
 
ASE
 
P
 
ATIENTS
 
(N
 

 
71)
C
 
ONTROLS
 
(N  68)
P
VALUE*
Age (yr)† 56.312.8 58.314.3 0.39
Male sex (%) 70 69 0.99
Hypertension (%)‡ 52 37 0.10
Current or former smoker (%) 72 55 0.05
Hypercholesterolemia (%)§ 26 22 0.69
Type I or II diabetes mellitus 
(%)
18 22 0.73
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ilarly high among case patients and control subjects. As
anticipated, the odds ratios for each of the risk factors,
including PlA2, were higher in the subgroup of case pa-
tients less than 60 years of age than in controls less
than 60 years of age. In this subgroup, the risk factor
associated with the highest estimated odds ratio was
again the PlA2 allele (odds ratio, 6.2; 95 percent conﬁ-
dence interval, 1.8 to 22.4), followed in order by smok-
ing (odds ratio, 3.8; 95 percent conﬁdence interval, 1.2
to 12.0), hypercholesterolemia (odds ratio, 3.7; 95 per-
cent conﬁdence interval, 0.8 to 18.7), and hypertension
(odds ratio, 2.1; 95 percent conﬁdence interval, 0.7 to
5.9) (Table 3).
A multiple logistic-regression model that adjusted for
the presence of smoking, hypertension, hypercholester-
olemia, and an age greater than 60 years provided an
odds ratio of 3.3 (95 percent conﬁdence interval, 1.4 to
7.7) for the relation between acute coronary events and
the PlA2 allele. This was consistent with the ﬁnding that
the bivariate association of the allele with smoking, hy-
pertension, hypercholesterolemia, and an age greater
than 60 years was uniformly not statistically signiﬁcant
(data not shown).
DISCUSSION
Our data demonstrate an association between the
PlA2 polymorphism of glycoprotein IIIa and the occur-
rence of acute coronary thrombosis. We found a signif-
icantly higher prevalence of subjects with at least one
PlA2 allele among those with either myocardial infarc-
tion or unstable angina than among a control group
matched for sex, age, and race. If this polymorphism
represents an inherited risk factor for myocardial in-
farction or unstable angina, one would predict an even
higher prevalence of this risk factor among persons in
whom these disorders occur at a younger age (before
the age of 60 years), and this is what we found.
Data from northern and central Europe estimate the
phenotypic frequency and genotypic frequency of PlA2
to be 26.5 percent and 15 percent, respectively.40 These
Figure 1. Genotyping of PlA Loci by Allele-
Speciﬁc Restriction Digestion and Re-
verse Dot Blot Hybridization.
Panel A shows the restriction map of exon
2 of the glycoprotein IIIa gene, undigested
fragments, and fragments resulting when
PlA1 or PlA2 PCR products were digested
with the restriction enzymes MspI and
NciI. Sizes (in base pairs) are indicated
below the horizontal lines. The vertical
bars indicate the ends of PCR fragments
or digestion products. For clarity and be-
cause it does not cause a detectable
change in the fragment sizes, an addition-
al MspI site (present in both PlA alleles)
7 bp from the 3 MspI site is not shown.
Panel B shows a representative ethidium-
stained 3 percent agarose gel containing
undigested PCR products (lanes 1, 5, and
8) and PCR products digested with MspI
(lanes 2, 6, and 9) and NciI (lanes 3, 7, and
10) corresponding to the three possible al-
lelic combinations: PlA1/PlA1 (lanes 1, 2,
and 3), PlA1/PlA2 (lanes 5, 6, and 7), and
PlA2/PlA2 (lanes 8, 9, and 10). Lane 4
shows X174 DNA cut with HaeIII, which
was used as a size marker. Panel C shows
the results of reverse dot blot hybridization
with the DNA shown in Panel B. Filters are
shown with PlA1-allele–speciﬁc oligonucle-
otides at the top and PlA2-allele–speciﬁc
oligonucleotides at the bottom.
3535
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estimates were derived from studying subjects whose
genetic background may differ from that of our sub-
jects. In our previous work, we determined that the
prevalence of PlA2 among 100 white subjects from the
Baltimore area was 20 percent (genotypic frequency, 11
percent).34 As compared with the subjects in the Euro-
pean studies, the control subjects in the current study
had a slightly lower prevalence of PlA2 (19.1 percent vs.
26.5 percent), but one that was virtually identical to the
prevalence in our previous study in Baltimore. Between
our two studies we have performed genotyping on 336
chromosomes from white control subjects, and the re-
sults provide very strong evidence that the prevalence
of PlA2 among these subjects in the metropolitan Balti-
more area is approximately 20 percent. For this reason,
we believe the data on control subjects in the current
study accurately reﬂect the population genetics in our
geographic area and that this group is a valid one to
use for comparison with our case patients.
Finally, although variation in the genetic background
is the most likely explanation for differences in the
prevalence of the PlA2 phenotype between the United
States and Europe, the earlier studies of European pop-
ulations used immunophenotyping, which is less specif-
ic than genotyping.
To assess the association between PlA2 and acute cor-
onary events, we compared the risk of having a coro-
nary event associated with the PlA2 polymorphism with
that associated with four major cardiac risk factors.
Among the major risk factors tested, the one associat-
ed with the largest odds ratio of having a coronary
event, both for the entire group and for the subgroup
of younger patients (age less than 60 years at ﬁrst
acute coronary event), was the PlA2 allele (Table 3). In
addition, we conducted a multiple logistic-regression
analysis adjusting for the presence of smoking, hyper-
tension, hypercholesterolemia, and an age greater than
60 years, which demonstrated an independent associa-
tion between PlA2 and acute coronary events. All the
risk factors tested yielded odds ratios consistent with
what one would expect for a major risk factor for cor-
onary heart disease, except for diabetes. However, we
believe that the low odds ratio associated with diabetes
is a result of the selection of control subjects from a
population of inpatients with a high prevalence of dia-
betes.
One theoretical explanation for the increased preva-
lence of PlA2 among the case patients could be a higher
survival rate after myocardial infarction in this group
than in PlA2-negative patients. However, if PlA2 did pro-
vide a survival advantage, the prevalence of PlA2 would
be unlikely to be increased among the case patients in
whom disease occurred before the age of 60 years. In-
stead, our hypothesis is that PlA2 is a risk factor for cor-
onary heart disease events, particularly among younger
persons. In fact, among the case patients, there was a
signiﬁcant difference of more than 7 years in the age at
onset of disease between the PlA2-positive patients and
the PlA2-negative patients (51.8 vs. 59.2 years, P0.02).
In addition to our ﬁndings related to the prognostic
potential of PlA2, our results could directly affect the
treatment of acute coronary events. For example, al-
though aspirin has been the platelet inhibitor of choice
for the treatment of unstable coronary syndromes, re-
*The total number of patients and controls for individual risk factors may not equal 71 and 68, respectively, since data were missing for some subjects. For the case
patients, age refers to the age at onset of myocardial infarction or unstable angina, not the current age. CI denotes conﬁdence interval.
†Subjects with the PlA1/PlA2 or PlA2/PlA2 genotype were classiﬁed as PlA2-positive.
‡The odds ratio was not calculated because the control subjects were selected from a population of inpatients with a high prevalence of diabetes.
Table 3. Odds Ratios for Selected Risk Factors, According to Age.*
FACTOR CLASS ALL AGES AGE 60 YR
NO. OF
CASE PATIENTS
NO. OF
CONTROLS
ODDS RATIO
(95% CI)
NO. OF
CASE PATIENTS
NO. OF
CONTROLS
ODDS RATIO
(95% CI)
PlA genotype PlA2-positive†
PlA2-negative
28
43
13
55
2.8 (1.2–6.4)
21
21
5
31
6.2 (1.8–22.4)
Smoking status Current or former
Never
50
19
36
30
2.2 (1.0–4.8)
32
8
18
17
3.8 (1.2–12.0)
Systolic blood pressure on ad-
mission
140 mm Hg
140 mm Hg
36
33
25
43
1.9 (0.9–3.9)
19
21
11
25
2.1 (0.7–5.9)
Total serum cholesterol on ad-
mission
200 mg/dl
200 mg/dl
18
50
15
53
1.3 (0.5–3.0)
10
30
3
33
3.7 (0.8–18.7)
Diabetes mellitus Type I or II
None
13
58
15
53
—‡
8
34
8
28
—‡
*Subjects with the PlA1/PlA1 genotype were classiﬁed as PlA2-negative,
and subjects with the PlA1/PlA2 or PlA2/PlA2 genotype were classiﬁed as
PlA2-positive. For the case patients, age refers to the age at onset of myo-
cardial infarction or unstable angina, not the current age.
†The chi-square test was used to compare the prevalence of PlA2 in case
patients and controls.
Table 2. Genotypes of the Case Patients and Con-
trols According to Age.*
GENOTYPE
CASE
PATIENTS CONTROLS
P
VALUE†
no. (%)
All ages
PlA1/PlA1
PlA1/PlA2PlA2/PlA2
Total
43 (60.6)
235 (39.4)
71 (100)
55 (80.9)
121 (19.1)
68 (100)
0.01
Age 60 yr
PlA1/PlA1
PlA1/PlA2PlA2/PlA2
Total
21 (50)
192 (50)
42 (100)
31 (86.1)
50 (13.9)
36 (100)
0.002
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cent studies indicate that treatment with speciﬁc inhib-
itors of glycoprotein IIb/IIIa leads to better outcomes
than does aspirin therapy.23-26,41 It is conceivable that
PlA2-positive patients would receive extra beneﬁt from
direct therapy with anti–glycoprotein IIb/IIIa, provid-
ing a rationale for decisions regarding the choice of an-
tiplatelet therapy for patients with unstable coronary
syndromes.41
We are indebted to the members of Kindred PT1 for their invalu-
able contribution to this study; to Hyun Kim, Emily E. Milliken, Ying
Jin, William S. Shear, and Lindsay D. Coleman for excellent technical
support; to Dr. Pamela Ouyang, Lydia Nelson, and members of the
medical house staff and nursing staff of Johns Hopkins Hospital for
assistance in the recruitment of patients and the procurement of
blood samples; to Drs. Kenneth L. Baughman and Roger Blumenthal
for providing medical records and scientiﬁc expertise; and to Dr. Paul
M. Ridker for thoughtful discussions.
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